Blog

Pharmacy Deserts, Access Disruptions, and a Threat to Medication Adherence: A Look Into 2026

Pharmacy closures are no longer a hypothetical risk: With pharmacy deserts expanding through 2025, employees face growing barriers to medication access, driving lower adherence, worse health outcomes, and measurable productivity loss for employers.

A Drug Shouldn't Out Earn Your Employees

In 2025, the average American working full-time earns about $66,622 a year. Now consider this: the average annual cost of specialty drugs is $84,000 a year.

Specialty Drug Prices Are Spiraling Far Beyond Inflation – Here’s How To Stop It

Many employers still rely on pharmacy benefit managers (PBMs) and traditional formularies that don’t reflect market efficiency or real-world value. But here’s the thing: you don’t have to absorb these costs.

Utah’s Rebate Pass‑Through Mandate: Why Waiting Until July 2026 Isn’t Worth It

Utah’s 2025 pharmacy benefit law, effective for health plans issued or renewed on or after July 1 2026, requires health insurers to ensure that PBMs pass 100% of manufacturer rebates directly to members at the point of sale or use them to lower premiums or enhance benefits.

2025 Premiums Spike: Why Employers Are Turning to Self-Funding (and What’s Still Missing)

Premiums are rising fast. In 2025, employer-sponsored single and family coverage hit $9,325 and $26,993, driving a major shift toward self-funding and level-funded arrangements across all employer sizes.

PBM Transparency: Opening the Black Box of Drug Pricing

In this rapidly evolving landscape, transparency is not just a regulatory buzzword – it is a competitive advantage.

By 2027, Specialty Medication Will Cost Insurers 56% of Their Whole Budget... But What If You Could Shrink That To 17%?

It’s projected that by 2027, 56% of total insurance spend will go to specialty medications. But what if that same slice could be shrunk down to just 17%?

63% and Climbing: Why Employers Are Surging Toward Being Self-Insured In 2025

Self‑funding is no longer restricted to Fortune 500 companies.